The HDAC inhibitor SAHA effectively inhibits tumor cell growth in multiple glioma cell lines and mouse models [79], [80], and a phase 2 clinical trial in patients with recurrent GBM showed modest single-agent activity [81]. Here, HDAC9 is linked to glioblastoma.